Lv21
140 积分 2025-02-21 加入
The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations
1个月前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
1个月前
已完结
Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
1个月前
已完结
EP.07E.03 TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma
2个月前
已关闭
Correlation Analysis of the TP53 Mutation With Clinical Characteristics in the Prognosis of Non–Small Cell Lung Cancer
2个月前
已完结
The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer
2个月前
已完结
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
2个月前
已完结
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)
2个月前
已完结
亚洲胸部肿瘤学协作组肺癌围术期管理专家共识
2个月前
已完结
Calling SNPs without a reference sequence
2个月前
已完结
皖公网安备34019202002308
